News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
The company's Bavla site was successfully jointly inspected by the EDQM and Italian Medicines Agency (AIFA)
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
